ATG Versus OKT3 in the Treatment of Steroid-Resistant Rejection Following Living-Related Donor Renal Transplantation

By Uslu A.   Tokat Y.   Ok E.   Unsal A.   Ilkgul O.   Kaplan H.  

Transplantation Proceedings, Vol. 29, Iss. 7, 1997-11 ,pp. : 2805-2806

Elsevier

Access to resources Recommend Favorite

OKT3 Induction Therapy and Cadaveric Renal Transplantation in Black Patients

By Reinitz E.R.   Kaplan M.P.   Sillix D.H.   Lysz K.  

Transplantation Proceedings, Vol. 29, Iss. 8, 1997-12 ,pp. : 3703-3705

Elsevier

Access to resources Recommend Favorite

Use of reduced dose of OKT3 (2.5 mg) after renal transplantation

By Machado P.G.P.   Tedesco H.S.   Silva R.G.   Pacheco-Silva A.   Medina J.O.P.  

Transplantation Proceedings, Vol. 34, Iss. 1, 2002-02 ,pp. : 104-104

Elsevier

Access to resources Recommend Favorite

A prospective randomized study comparing poly-ATG to mono-OKT3 clonal antibodies for the first rejection therapy after kidney transplantation: long-term results

By Baldi A.   Malaise J.   Mourad M.   Squifflet J.P.  

Transplantation Proceedings, Vol. 32, Iss. 2, 2000-03 ,pp. : 429-431

Elsevier

Access to resources Recommend Favorite

One center's experience with OKT3 in renal transplantation: patient and graft survival, complications, and cost analysis

By Guz G.   Emiroglu R.   Demirhan B.   Koseoglu F.   Karakayali H.   Bilgin N.  

Transplantation Proceedings, Vol. 32, Iss. 3, 2000-05 ,pp. : 572-573

Elsevier

Access to resources Recommend Favorite